about
Rotavirus Vaccine Schedules and Vaccine Response Among Infants in Low- and Middle-Income Countries: A Systematic Review.Reduction in diarrhoeal rates through interventions that prevent unnecessary antibiotic exposure early in life in an observational birth cohortCharacterization of enterotoxigenic Escherichia coli strains isolated from Nicaraguan children in hospital, primary care and community settingsHousehold management of childhood diarrhoea: a population-based study in Nicaragua.HPV vaccine acceptability among Kenyan women.Etiology of childhood diarrhea after rotavirus vaccine introduction: a prospective, population-based study in Nicaragua.Changes in childhood diarrhea incidence in nicaragua following 3 years of universal infant rotavirus immunization.Patterns of rotavirus vaccine uptake and use in privately-insured US infants, 2006-2010.Trends in antibiotic treatment of acute otitis media and treatment failure in children, 2000-2011.Association between intimate partner violence and irritable bowel syndrome: a population-based study in NicaraguaRotavirus-specific IgG antibodies from mothers' serum may inhibit infant immune responses to the pentavalent rotavirus vaccine.Rotavirus prevalence in the primary care setting in Nicaragua after universal infant rotavirus immunizationThe effect of early life antibiotic exposures on diarrheal rates among young children in Vellore, India.Gut Microbiome Composition in Young Nicaraguan Children During Diarrhea Episodes and Recovery.Irritable bowel syndrome and gastrointestinal parasite infection in a developing nation environment.Antibiotic treatment of diarrhoea is associated with decreased time to the next diarrhoea episode among young children in Vellore, IndiaBoth Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner.Nursing home nurses' and community-dwelling older adults' reported knowledge, attitudes, and behavior toward antibiotic useCommunity diarrhea incidence before and after rotavirus vaccine introduction in Nicaragua.Early Life Antibiotic Exposure Is Not Associated with Growth in Young Children of Vellore, India.Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries.Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007-2010.Innate Immune Factors in Mothers' Breast Milk and Their Lack of Association With Rotavirus Vaccine Immunogenicity in Nicaraguan Infants.Pneumococcal Carriage and Vaccine Coverage in Retirement Community Residents.Changes in the incidence of pneumonia, bacterial meningitis, and infant mortality 5 years following introduction of the 13-valent pneumococcal conjugate vaccine in a "3+0" schedule.Predictors of Low Uptake of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Immunization in Privately Insured Women in the United States.Prenatal Tdap immunization and risk of maternal and newborn adverse events.Patterns of Use of Human Papillomavirus and Other Adolescent Vaccines in the United States.Risk Factors for Norovirus Gastroenteritis among Nicaraguan Children.The Association Between Fecal Biomarkers of Environmental Enteropathy and Rotavirus Vaccine Response in Nicaraguan Infants.Pediatric norovirus GII.4 infections in Nicaragua, 1999-2015.Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua.Impact of a combined pediatric and adult pneumococcal immunization program on adult pneumonia incidence and mortality in Nicaragua.Changes in Pneumonia Incidence and Infant Mortality 5 Years Following Introduction of the 13-valent Pneumococcal Conjugate Vaccine in a “3+0” Schedule in Nicaragua.United States Travelers' Concern about Zika Infection and Willingness to Receive a Hypothetical Zika Vaccine.Zika Virus Prevention: U.S. Travelers' Knowledge, Risk Perceptions, and Behavioral Intentions-A National Survey.Review: Evidence of Neurological Sequelae in Children With Acquired Zika Virus InfectionGenetic diversity of human sapovirus across the AmericasGenetic diversity of human sapovirus across the AmericasProlonged Shedding of Zika Virus RNA in Vaginal Secretions, Nicaragua
P50
Q30234306-54A07FEC-0C36-4FA8-A4F1-7BC6BACECC14Q30356480-0F3009E1-8381-44DC-905B-D1C669953D34Q33702578-3FC0F2B7-49CE-470A-B442-0B3F52C27752Q33871128-4934F250-D5F1-4B51-90A5-1F3198EF9DB5Q34005291-4EC11952-4409-4FD2-B1CB-6BE6E7081B97Q34437732-FB8050F1-87AF-477A-A9DF-E27E04977F97Q34574440-79B0DA52-C669-4A76-BBC9-9F384904C959Q34997107-C46B7930-41C2-40D8-BF99-4D0E519668F5Q35063926-87E17824-877F-4776-8237-CF7735E76530Q35079562-08400544-2667-4F42-BCCA-9F56BCFB0611Q35156714-D9A508A6-0E1C-4539-BB44-C0C737A77DD4Q35494648-76825F64-FEA7-40FE-B098-BD33570E5949Q35607073-5EE5E16C-BAC8-43F3-9CD4-128536672EC4Q35767241-03B18FF9-386A-4ECC-BE67-64DC2BEFAAEBQ35810402-13682802-D508-411D-95CD-1870C6823981Q36167528-BA62310F-8D45-4D37-A17F-094BA310229AQ36293984-A6B174BE-73D7-47D4-940F-01116C8A2019Q36307962-E3D986A5-F11C-4496-A9AF-752096C80514Q37089583-45B0224D-8EA8-4FA8-8E08-0B8A19CF7C68Q37271313-EA47C119-C7B0-4091-A5E8-A873A89DA6FAQ37563622-915C1C17-CF5D-4CB6-9DE6-86576DB4F9FEQ37671911-3868AB9E-52F0-4C24-ACF6-6B92150EE948Q38420378-284F9647-9228-4191-B77C-D9104D3C5724Q38604515-2C5362A0-6BC8-416A-8782-7C436432BAAEQ38622148-4F9BEC9D-E9C4-4F1D-A582-49A6076070C6Q38918145-67593818-E422-4D7C-862E-D63CADD40EC5Q40050338-4BCD93D2-B658-41F7-B496-E94E9A486695Q40110263-D0CAB17D-558C-4D9F-8AC3-3EE731F65D86Q40117061-92D1ECDE-1BBA-4893-B323-462FD03E2CC9Q40424154-03C9A6B1-13AF-400F-92B4-0FEB3306DAF2Q41923407-C789A8BC-C696-4750-89D3-8598E76A3409Q42232148-E30BF329-2274-479C-833E-CD6DFBA9D8B0Q44236629-59BB35A6-3E5C-4810-BFA9-E4A7B0064658Q50350883-202BE0F7-B47C-4B99-986C-E40DA2FF73E2Q53071523-5458CCFE-90CD-40EB-89CB-32259FA84A48Q54558435-05BD8044-3866-446B-967A-AA80AA0EC7D8Q57824626-8A17EAAB-0FE9-4913-8EF8-4ABCACDE6E94Q59093031-EFAD0092-415E-412D-A954-8295021F964CQ59360982-0A9F47F3-9ABD-4EE8-9823-218CC407838AQ62485197-285714C6-78A6-498F-87B0-57119F107366
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sylvia Becker-Dreps
@ast
Sylvia Becker-Dreps
@en
Sylvia Becker-Dreps
@es
Sylvia Becker-Dreps
@nl
type
label
Sylvia Becker-Dreps
@ast
Sylvia Becker-Dreps
@en
Sylvia Becker-Dreps
@es
Sylvia Becker-Dreps
@nl
prefLabel
Sylvia Becker-Dreps
@ast
Sylvia Becker-Dreps
@en
Sylvia Becker-Dreps
@es
Sylvia Becker-Dreps
@nl
P106
P31
P496
0000-0002-7808-2507